THYREL TRH
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYREL TRH is a small-molecule injectable diagnostic agent approved in 1978 by Ferring Pharmaceuticals. The product's mechanism of action and specific indications are not publicly detailed in available data, limiting clarity on its therapeutic role. It is administered via injection and classified as a traditional new drug application (NDA).
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a contracting commercial footprint and likely smaller field organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYREL TRH currently has zero linked open positions, reflecting its mature, stable product status with minimal growth trajectory. Careers on this product focus on operational efficiency and harvest-phase management rather than strategic expansion or innovation.
Brand ManagerField Sales Representative
Worked on THYREL TRH at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.